ANI Pharma reports record Q1 revs $106.8M (+65.6% YoY), raises FY2023 guidance across all metrics

ANI PHARMACEUTICALS INC

2023-Q1 EPS reported $0.06 revenue$106,786,000

Record net revenue of $106.8M, up 65.6% YoY; GAAP net income $1.0M, diluted EPS $0.06.
Adjusted non-GAAP EBITDA $33.0M (vs $4.3M Q1 2022); adj. diluted EPS $1.17 (vs -$0.12).
Cortrophin Gel net sales $16.3M (Q1 2022: $1.3M); FY guidance maintained at $80-90M.
Raised FY2023 guidance: rev $385-410M (from $360-385M), adj. EBITDA $97-107M, adj. EPS $2.99-3.45.
Generics revenue $63.7M (+29.7% YoY); established brands/other $26.7M (+90.0%). FDA inspection with zero 483s.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ANI PHARMACEUTICALS INC reported full-year 2023 results: revenue $385 million to $410 million, EPS $2.99 to $3.45. Guidance raised.

Period: full-year 2023
Revenue: $385 million to $410 million
EPS: $2.99 to $3.45
Guidance: raised
Result: guidance update

Exact text from the filing

Full Year 2023 Guidance -- Raises Company net revenue guidance to $385 million to $410 million from $360 million to $385 million; adjusted non-GAAP EBITDA guidance to $97 million to $107 million from $78 million to $88 million; adjusted non-GAAP earnings per share to $2.99 to $3.45 from $2.09 to $2.59

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ANI PHARMACEUTICALS INC reported quarter ended March 31, 2023 results: revenue $106.8 million, net income $1.0 million, EPS $0.06.

Period: quarter ended March 31, 2023
Revenue: $106.8 million
Net income: $1.0 million
EPS: $0.06
Result: reported results

Exact text from the filing

First Quarter 2023 Financial Results -- Record quarterly net revenues of $106.8 million, representing year-over-year growth of 65.6%; 2023 first-quarter net income available to common shareholders of $1.0 million and diluted GAAP income per share of $0.06

View on SEC.gov

Browse all earnings releases →

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-056889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.